Annual CFO
$8.80 M
+$68.31 M+114.79%
31 December 2023
Summary:
ADMA Biologics annual cash flow from operations is currently $8.80 million, with the most recent change of +$68.31 million (+114.79%) on 31 December 2023. During the last 3 years, it has risen by +$121.17 million (+107.83%). ADMA annual CFO is now at all-time high.ADMA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$25.03 M
-$20.62 M-45.17%
30 September 2024
Summary:
ADMA Biologics quarterly cash flow from operations is currently $25.03 million, with the most recent change of -$20.62 million (-45.17%) on 30 September 2024. Over the past year, it has increased by +$7.43 million (+42.23%). ADMA quarterly CFO is now -45.17% below its all-time high of $45.65 million, reached on 30 June 2024.ADMA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$86.05 M
+$13.04 M+17.86%
30 September 2024
Summary:
ADMA Biologics TTM cash flow from operations is currently $86.05 million, with the most recent change of +$13.04 million (+17.86%) on 30 September 2024. Over the past year, it has increased by +$77.25 million (+877.88%). ADMA TTM CFO is now at all-time high.ADMA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADMA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +42.2% | +877.9% |
| 3 y3 years | +107.8% | +174.8% | +176.6% |
| 5 y5 years | +111.5% | +227.4% | +212.9% |
ADMA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +107.8% | -45.2% | +174.8% | at high | +176.6% |
| 5 y | 5 years | at high | +107.8% | -45.2% | +174.8% | at high | +170.8% |
| alltime | all time | at high | +107.8% | -45.2% | +174.8% | at high | +170.8% |
ADMA Biologics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $25.03 M(-45.2%) | $86.05 M(+17.9%) |
| June 2024 | - | $45.65 M(-2158.0%) | $73.01 M(+242.7%) |
| Mar 2024 | - | -$2.22 M(-112.6%) | $21.30 M(+142.1%) |
| Dec 2023 | $8.80 M(-114.8%) | $17.60 M(+46.8%) | $8.80 M(-154.4%) |
| Sept 2023 | - | $11.98 M(-297.8%) | -$16.18 M(-61.0%) |
| June 2023 | - | -$6.06 M(-58.8%) | -$41.45 M(-14.0%) |
| Mar 2023 | - | -$14.72 M(+99.5%) | -$48.22 M(-19.0%) |
| Dec 2022 | -$59.51 M(-47.0%) | -$7.38 M(-44.5%) | -$59.51 M(-30.5%) |
| Sept 2022 | - | -$13.28 M(+3.5%) | -$85.59 M(-0.1%) |
| June 2022 | - | -$12.83 M(-50.7%) | -$85.72 M(-18.5%) |
| Mar 2022 | - | -$26.01 M(-22.3%) | -$105.15 M(-6.4%) |
| Dec 2021 | -$112.37 M(+10.2%) | -$33.47 M(+149.5%) | -$112.37 M(+1.1%) |
| Sept 2021 | - | -$13.41 M(-58.4%) | -$111.12 M(-8.6%) |
| June 2021 | - | -$32.26 M(-2.9%) | -$121.56 M(+9.9%) |
| Mar 2021 | - | -$33.23 M(+3.1%) | -$110.59 M(+8.4%) |
| Dec 2020 | -$102.00 M(+33.9%) | -$32.22 M(+35.1%) | -$102.00 M(+14.1%) |
| Sept 2020 | - | -$23.85 M(+12.1%) | -$89.44 M(+0.2%) |
| June 2020 | - | -$21.28 M(-13.6%) | -$89.21 M(+3.1%) |
| Mar 2020 | - | -$24.65 M(+25.4%) | -$86.55 M(+13.6%) |
| Dec 2019 | -$76.19 M(+21.6%) | -$19.65 M(-16.8%) | -$76.19 M(+1.1%) |
| Sept 2019 | - | -$23.63 M(+26.9%) | -$75.33 M(+17.3%) |
| June 2019 | - | -$18.62 M(+30.4%) | -$64.25 M(+6.1%) |
| Mar 2019 | - | -$14.29 M(-24.0%) | -$60.53 M(-3.4%) |
| Dec 2018 | -$62.68 M(+68.2%) | -$18.79 M(+49.8%) | -$62.68 M(+9.5%) |
| Sept 2018 | - | -$12.54 M(-15.9%) | -$57.24 M(+5.2%) |
| June 2018 | - | -$14.91 M(-9.3%) | -$54.44 M(+12.7%) |
| Mar 2018 | - | -$16.43 M(+23.0%) | -$48.31 M(+29.6%) |
| Dec 2017 | -$37.27 M | -$13.36 M(+37.2%) | -$37.27 M(+35.4%) |
| Sept 2017 | - | -$9.74 M(+11.0%) | -$27.53 M(+22.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | -$8.78 M(+62.6%) | -$22.47 M(+21.5%) |
| Mar 2017 | - | -$5.40 M(+49.4%) | -$18.50 M(+1.3%) |
| Dec 2016 | -$18.27 M(+18.5%) | -$3.61 M(-22.8%) | -$18.27 M(-2.5%) |
| Sept 2016 | - | -$4.68 M(-2.5%) | -$18.73 M(+12.0%) |
| June 2016 | - | -$4.80 M(-7.0%) | -$16.72 M(+2.2%) |
| Mar 2016 | - | -$5.17 M(+26.7%) | -$16.37 M(+6.1%) |
| Dec 2015 | -$15.42 M(+4.9%) | -$4.08 M(+52.6%) | -$15.42 M(+8.3%) |
| Sept 2015 | - | -$2.67 M(-39.9%) | -$14.24 M(+1.5%) |
| June 2015 | - | -$4.45 M(+5.3%) | -$14.04 M(+1.1%) |
| Mar 2015 | - | -$4.22 M(+45.4%) | -$13.89 M(-5.6%) |
| Dec 2014 | -$14.70 M(+35.1%) | -$2.90 M(+17.7%) | -$14.70 M(-0.4%) |
| Sept 2014 | - | -$2.47 M(-42.6%) | -$14.76 M(+1.7%) |
| June 2014 | - | -$4.30 M(-14.8%) | -$14.52 M(+13.0%) |
| Mar 2014 | - | -$5.04 M(+70.3%) | -$12.85 M(+18.1%) |
| Dec 2013 | -$10.89 M(+57.7%) | -$2.96 M(+33.0%) | -$10.89 M(+11.8%) |
| Sept 2013 | - | -$2.23 M(-15.3%) | -$9.73 M(+1.3%) |
| June 2013 | - | -$2.63 M(-14.6%) | -$9.61 M(+20.4%) |
| Mar 2013 | - | -$3.07 M(+70.2%) | -$7.98 M(+15.6%) |
| Dec 2012 | -$6.90 M(>+9900.0%) | -$1.81 M(-14.0%) | -$6.90 M(+35.1%) |
| Sept 2012 | - | -$2.10 M(+110.8%) | -$5.11 M(+69.6%) |
| June 2012 | - | -$996.90 K(-50.1%) | -$3.01 M(+48.9%) |
| Mar 2012 | - | -$2.00 M(>+9900.0%) | -$2.02 M(+6739.2%) |
| Dec 2011 | - | -$12.80 K(+146.2%) | -$29.60 K(+14.7%) |
| Sept 2011 | - | -$5200.00(-32.5%) | -$25.80 K(-11.0%) |
| June 2011 | -$29.00 K(+47.2%) | -$7700.00(+97.4%) | -$29.00 K(+36.2%) |
| Mar 2011 | - | -$3900.00(-56.7%) | -$21.30 K(+22.4%) |
| Dec 2010 | - | -$9000.00(+7.1%) | -$17.40 K(+107.1%) |
| Sept 2010 | - | -$8400.00 | -$8400.00 |
| June 2010 | -$19.70 K | - | - |
FAQ
- What is ADMA Biologics annual cash flow from operations?
- What is the all time high annual CFO for ADMA Biologics?
- What is ADMA Biologics quarterly cash flow from operations?
- What is the all time high quarterly CFO for ADMA Biologics?
- What is ADMA Biologics quarterly CFO year-on-year change?
- What is ADMA Biologics TTM cash flow from operations?
- What is the all time high TTM CFO for ADMA Biologics?
- What is ADMA Biologics TTM CFO year-on-year change?
What is ADMA Biologics annual cash flow from operations?
The current annual CFO of ADMA is $8.80 M
What is the all time high annual CFO for ADMA Biologics?
ADMA Biologics all-time high annual cash flow from operations is $8.80 M
What is ADMA Biologics quarterly cash flow from operations?
The current quarterly CFO of ADMA is $25.03 M
What is the all time high quarterly CFO for ADMA Biologics?
ADMA Biologics all-time high quarterly cash flow from operations is $45.65 M
What is ADMA Biologics quarterly CFO year-on-year change?
Over the past year, ADMA quarterly cash flow from operations has changed by +$7.43 M (+42.23%)
What is ADMA Biologics TTM cash flow from operations?
The current TTM CFO of ADMA is $86.05 M
What is the all time high TTM CFO for ADMA Biologics?
ADMA Biologics all-time high TTM cash flow from operations is $86.05 M
What is ADMA Biologics TTM CFO year-on-year change?
Over the past year, ADMA TTM cash flow from operations has changed by +$77.25 M (+877.88%)